Steve Fordan, MD
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1245432582
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,084,906 of the $1,228,460 with a category attached, or 88.3%. 60 manufacturers reported payments, led by Lilly USA, LLC at 51.5% of the total. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,106 payments — averaging $395.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$633K
- Novo Nordisk$280K
- Boehringer Ingelheim$102K
- Bayer$78K
- Sanofi-aventis U.S. LLC$38K
- Merck$35K
- plus $63K from 54 others
Across 1,775 payments — averaging $898.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$907K
- Eli Lilly$450K
- Kowa Research Institute, Inc.$78K
- Amgen$59K
- Sanofi US Services Inc.$50K
- Bayer$27K
- plus $22K from 1 others
What the payments were for
- Consulting fees$15,6601%
- Speaking & faculty fees$1,084,90688%
- Travel & lodging$78,2086%
- Food & beverage$49,3504%
- Education$2180%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$223,629
- TRULICITY$219,682
- JARDIANCE$210,903
- Ozempic$157,045
- RYBELSUS$103,900
- Kerendia$74,977
- STEGLATRO$33,543
- SOLIQUA 100/33$29,967
- BAQSIMI$15,000
- TOUJEO$13,273
- HUMULIN$12,800
- Tresiba$11,846
- FARXIGA$11,387
- GVOKE PFS$7,349
- AFREZZA$5,042
- INVOKANA$4,320
- ZEGALOGUE$2,560
- V-GO$1,913
- FreeStyle Libre$1,592
- Synthroid$900
How this compares
$1,228,460 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 209 | $300,813 |
| MounjaroTirzepatide | 147 | $219,717 |
| JardianceEmpagliflozin | 155 | $163,943 |
| TrulicityDulaglutide | 78 | $143,137 |
| RybelsusSemaglutide | 54 | $65,580 |
| FarxigaDapagliflozin Propanediol | 60 | $62,725 |
| ForteoTeriparatide | 11 | $54,011 |
| Tresiba Flextouch U-200Insulin Degludec | 51 | $50,677 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $46,991 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $41,343 |
| TradjentaLinagliptin | 36 | $39,552 |
| Repatha SureclickEvolocumab | 35 | $38,967 |
| Tresiba Flextouch U-100Insulin Degludec | 58 | $32,862 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $32,186 |
| Repatha SyringeEvolocumab | 28 | $28,379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Insulin Lispro | $633,024 | $421,581262 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $279,794 | $386,541287 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Trijardy Xr, Glyxambi | $102,310 | $256,065243 claims |
| AstraZenecaFarxiga | $12,551 | $62,72560 claims |
| BayerKerendia | $78,055 | $24,98036 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset | $113 | $10,07611 claims |
| Astellas Pharma US IncVeozah | $278 | $8,21412 claims |
| AbbVieSynthroid | $1,544 | $7,72078 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Dallas
- Pablo MoraDallas$1.3M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Ildiko LingvayDallas$711K
- Rajiv DattatreyaDallas$437K
- Jaime AlmandozDallas$334K
- Luigi MeneghiniDallas$136K
- Oksana HamidiDallas$106K
- Lance SloanLufkin$1.7M
- Robert HoodBeaumont$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.